Evidence map›Paper›PMID 30171865›Full record

ArticleExperimental neurology2018

Pretreatment with low-dose fimasartan ameliorates NLRP3 inflammasome-mediated neuroinflammation and brain injury after intracerebral hemorrhage.

Xiuli Yang, Jing Sun, Tae Jung Kim, Young-Ju Kim, Sang-Bae Ko, Chi Kyung Kim, Xiaofeng Jia, Byung-Woo Yoon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. New targets in spontaneous intracerebral hemorrhage.Current opinion in neurology · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases.Molecules (Basel, Switzerland) · 2021
    Review
  20. Revisiting promising preclinical intracerebral hemorrhage studies to highlight repurposable drugs for translation.International journal of stroke : official journal of the International Stroke Society · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiuli YangDepartment of Neurology, Seoul National University Hospital, Seoul 03080, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea; Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Jing SunBiomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea; Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, 130000 Jilin, China.
Tae Jung KimDepartment of Neurology, Seoul National University Hospital, Seoul 03080, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.
Young-Ju KimDepartment of Neurology, Seoul National University Hospital, Seoul 03080, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.
Sang-Bae KoDepartment of Neurology, Seoul National University Hospital, Seoul 03080, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.
Chi Kyung KimDepartment of Neurology, Korea University Guro Hospital, Seoul 08308, Republic of Korea.
Xiaofeng JiaDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Anatomy Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: xjia@som.umaryland.edu.
Byung-Woo YoonDepartment of Neurology, Seoul National University Hospital, Seoul 03080, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea; Neuroscience Research Institute, Seoul National University College of Medicine, Seoul 03087, Republic of Korea. Electronic address: bwyoon@snu.ac.kr.

Funding

Brain Monitoring and Therapeutic Hypothermia after Cardiac ArrestR01HL118084 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI JIA, XIAOFENG · 2013 to 2018
$1.9M
Brain Recovery after Cardiac Arrest with Metabolic Glycoengineered Stem CellsR01NS110387 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI JIA, XIAOFENG · 2018 to 2022
$1.7M
NHLBI NIH HHS R01 HL118084NINDS NIH HHS R01 NS110387
6 · The paper itself

Abstract

Nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, which is composed of an NLRP3 domain, the adaptor molecule apoptosis-associated speck-like protein containing a CARD (ASC) domain, and procaspase-1, plays an important role in the immune pathophysiology of the secondary damage induced by intracerebral hemorrhage (ICH). This study aims to investigate whether pre-stroke treatment with fimasartan, an angiotensin II receptor blocker, has anti-inflammatory effects on ICH by inhibiting the activation of the NLRP3 inflammasome. Sprague-Dawley rats were divided into five groups: sham, vehicle, low-dose (0.5 mg/kg) and regular-doses (1.0 and 3.0 mg/kg) fimasartan. These rats were treated for 30 days before the induction of collagenase-induced ICH and continuously 3 days after surgery. The mean blood pressure (BP) in the low-dose fimasartan group was not significantly different from that of control, and BP in the regular-dose groups was decreased in a dose-dependent manner. Pretreatment with low-dose fimasartan attenuated ICH-induced edema and improved neurological functions. Activation of the NLRP3/ASC/caspase-1 and the NF-κB pathways after ICH was markedly reduced by low-dose fimasartan. The double immunofluorescence staining of brain cells showed a significant decrease in the co-localization of NLRP3 with Iba1 (microglia marker) positive cells by fimasartan treatment. Cultured microglia cells stimulated by hemolysate demonstrated significant activation of the inflammasome, which was reduced by fimasartan. Pretreatment with a low-dose fimasartan alleviated brain damage after acute ICH by inhibiting the NLRP3 inflammasome without lowering MBP. Our study suggests pre-stroke administration of fimasartan could potentially attenuate ICH-induced secondary brain injury by targeting the inflammasome.

Indexed as

AnimalsBiphenyl CompoundsBlood PressureBrain EdemaBrain InjuriesCalcium-Binding ProteinsCells, CulturedCerebral HemorrhageCytokinesDisease Models, AnimalDose-Response Relationship, DrugEncephalitisGlial Fibrillary Acidic ProteinMaleMicrofilament ProteinsMicrogliaAif1 protein, ratBiphenyl CompoundsCalcium-Binding ProteinsCytokinesfimasartanGlial Fibrillary Acidic ProteinMicrofilament ProteinsNeuroprotective AgentsNLR Family, Pyrin Domain-Containing 3 ProteinPyrimidinesTetrazolesBrain injuryIntracerebral hemorrhageNLRP3 inflammasomeStroke

Identifiers

PMID30171865
PMCPMC6203658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.